BriaCell is developing personalized peptide-and-cell immunotherapy for metastatic cancer, with two programs anchoring the pipeline. Bria-IMT — a whole-cell allogeneic immunotherapy — is in Phase 3 in advanced metastatic breast cancer, with positive quality-of-life and biomarker data presented at AACR 2026 and six accepted abstracts at ASCO 2026 covering 12- and 24-month survival, treatment tolerability, and circulating-tumor-cell biomarker work. The next-generation Bria-OTS+ platform pairs HLA-matched cells with peptide-mediated antigen targeting; preclinical anti-cancer data presented at AACR 2026 (April 21) supports planned clinical entry for metastatic breast and prostate cancer late 2026, with lung and melanoma indications targeted for 2027.
The Phase 3 patient-enrollment update remains on track for 1H 2026 topline data, and the Bria-ABC randomized Phase 3 also features a blood-biomarker progression-free-survival readout. Stories here cover trial readouts, AACR and ASCO presentations, and the broader peptide-immunotherapy field. See #bria-imt, #peptide-vaccine, and #metastatic-breast-cancer.
BriaCell's three June 1 poster presentations moved past the previously reported 16.6-month Phase 2 median overall survival to the first blinded data from the pivotal Phase 3 Bria-ABC study: sustained quality of life despite advanced disease and a meaningful TWiST (time without symptoms or toxicity) result. Biomarker tracking continued, with stable or decreasing CAML counts correlating with better progression-free survival in 60% of evaluable patients. The Phase 3 regimen starts the checkpoint inhibitor in Cycle 1 and uses a Bria-IMT formulation without interferon-gamma.
BriaCell Therapeutics priced a registered direct offering of 1,449,300 common shares at $3.25 each for gross proceeds of about $4.7 million, with ThinkEquity as sole placement agent. The company plans to use proceeds for working capital, general corporate purposes, and advancing its pipeline. The raise lands days after BriaCell reported 16.6-month median overall survival for its Bria-IMT cell-based immunotherapy in heavily pretreated metastatic breast cancer at ASCO 2026.
BriaCell's ASCO 2026 poster presentations added a biomarker finding beyond the headline 16.6-month median overall survival for Bria-IMT. In an ongoing analysis of heavily pretreated metastatic breast cancer patients, 65% showed stability or a drop in Cancer-Associated Macrophage-Like cells (CAMLs) — circulating cells in the blood that reflect tumor activity — and that change significantly correlated with better progression-free survival. The CAML biomarker offers a potential early blood-based readout of Bria-IMT response, which matters for an immunotherapy where conventional imaging can lag the immune response. BriaCell's six ASCO 2026 data items (three posters, three publication-only abstracts) cover the pivotal Phase 3 Bria-ABC study of Bria-IMT plus checkpoint inhibitor plus further Phase 2 analyses. Bria-IMT is a whole-cell allogeneic peptide-and-cell immunotherapy in heavily pretreated metastatic breast cancer that has failed ADC, checkpoint, and CDK4/6 inhibitor therapy. The biomarker work supports patient selection and response monitoring as the program advances toward accelerated-approval discussions.
The ASCO 2026 Annual Meeting opens tomorrow Friday May 29 at McCormick Place Chicago, running through June 2. The peptide-and-targeted-conjugate oncology slate that landed in the May 21 abstract release and the May 26 embargoed press briefing: Bicycle Therapeutics Duravelo-2 Phase 2 (zelenectide pevedotin 65% ORR / 58% BICR-confirmed in 1L urothelial, oral June 1 8:30 AM); Avacta AVA6000 FAP-Dox Phase 1a/1b in salivary gland (90% disease control); BriaCell Bria-IMT 16.6-month median OS in metastatic breast cancer; Sapience lucicebtide 28.4-month projected median PFS in glioblastoma; Corbus CRB-701 Nectin-4 ADC in HNSCC and cervical (oral May 29); Crinetics CRN09682 SSTR2 non-peptide drug conjugate BRAVESST2; Aktis AKY-2519 B7-H3 miniprotein radioconjugate; Mayo Clinic TPIV200 folate-receptor peptide vaccine in TNBC; plus the GLP-1 cancer slate (Abstract 3143, Roswell Park breast cancer). ASCO 2026 follows immediately after EASL 2026 closes May 30 — the back-to-back meeting structure makes the May 27-June 2 window the highest-density peptide-data week of 2026.
ASCO 2026 in Chicago opens Friday May 29 with the peptide-oncology calendar now fully fixed. Thursday May 29 4:57 PM CDT: Corbus CRB-701 Nectin-4 ADC oral session in cervical cancer. Friday May 30 4:30 PM CDT: Corbus CRB-701 HNSCC poster. Saturday May 30: BriaCell Bria-IMT three posters in metastatic breast cancer. Sunday May 31: Bicycle Therapeutics zelenectide pevedotin Phase 1 Duravelo-1 monotherapy update poster; Avacta AVA6000 FAP-Dox Phase 1a/1b in salivary gland cancers poster session. Monday June 1 8:30-8:36 AM CT: Bicycle Therapeutics Duravelo-2 oral abstract (Abstract 4516). Monday June 1: Sapience Therapeutics lucicebtide poster session for newly-diagnosed GBM. The peptide-oncology cohort is the largest single-meeting concentration of peptide-mechanism oncology data in recent ASCO history.
BriaCell's formal post-ASCO 2026 press release Friday morning specified the headline number from yesterday's abstract release. Final Phase 2 median overall survival with Bria-IMT plus checkpoint inhibitor reached 16.6 months in heavily pretreated metastatic breast cancer patients using the Phase 3 formulation — a substantial improvement over historical post-ADC, post-CPI, post-CDK4/6-failure populations where median OS typically runs 8-10 months. The release also specified positive quality-of-life data from the ongoing Phase 3 study and biomarker analyses confirming the predictors of anti-cancer response observed in Phase 2 carry forward into the Phase 3 cohort. The three poster presentations plus three publication-only abstracts at ASCO 2026 (May 29-June 2) will detail 12- and 24-month survival, treatment tolerability, and circulating-tumor-cell biomarker work. The 16.6-month median OS sets the bar BriaCell needs to clear or beat in the ongoing Phase 3 to support its accelerated approval ambitions.
ASCO 2026 abstract text released at 5 PM ET Thursday, ahead of the May 29-June 2 Chicago meeting. The peptide-oncology data landed simultaneously across the previously-announced slate. Bicycle Therapeutics released Duravelo-2 Phase 2/3 interim data on zelenectide pevedotin (BT8009) plus pembrolizumab in 1L locally advanced/metastatic urothelial cancer. Avacta released AVA6000 Phase 1b data in salivary gland cancers. BriaCell released final Phase 2 Bria-IMT survival data plus biomarker analyses from the ongoing Phase 3. BioVaxys's MVP-S PESCO Phase 1B/2 ovarian cancer abstract landed. Crinetics CRN09682 SSTR2 NDC BRAVESST2 abstract emerged. Pfizer released 40+ company-sponsored, investigator-sponsored, and collaborative oncology abstracts including three late-breaking sessions. The peptide-oncology cohort is the largest single ASCO presence in recent meeting history.
BriaCell released final randomized Phase 2 Bria-IMT survival and quality-of-life data at ASCO 2026 alongside biomarker analyses from the ongoing Phase 3 study. Bria-IMT — a whole-cell allogeneic peptide-and-cell immunotherapy combined with checkpoint inhibitor — has been studied in heavily pretreated metastatic breast cancer patients who have failed antibody-drug conjugate, checkpoint, and CDK4/6 inhibitor therapy. The Phase 2 data set covers 12- and 24-month survival, treatment tolerability, and circulating-tumor-cell biomarker work. The Phase 3 program added Penn Medicine's Abramson Cancer Center as a site on May 13, joining Smilow Cancer Hospital at Yale New Haven and the Los Angeles Cancer Network. The six-abstract BriaCell package at ASCO 2026 — three poster presentations and three publication-only abstracts — establishes the company as the largest peptide-immunotherapy presence at this year's meeting.
BriaCell announced May 15 it has expanded its pipeline to include Bria-OVA+, a next-generation personalized off-the-shelf cell-based immunotherapy for ovarian cancer. The company licensed ovarian-cancer cell lines from American Type Culture Collection (ATCC) and has commenced development activities to support production of Bria-OVA+ for potential clinical use. The candidate is designed with additional immune-stimulating components to support enhanced anti-tumor activity, building on Phase 2 efficacy and tolerability data in metastatic breast cancer. The company is targeting ovarian cancer because an estimated 21,010 women in the US will be diagnosed in 2026 and approximately 12,450 will die from the disease, with ovarian cancer remaining the deadliest gynecologic cancer. The expansion adds to the BriaCell platform spanning Bria-IMT (metastatic breast), Bria-OTS+ (next-gen breast and prostate), Bria-PROS+ (prostate), and Bria-BRES+ (breast).
BriaCell announced May 14 it has completed manufacturing of clinical supplies for Bria-PROS+, the company's prostate cancer cell-based immunotherapy candidate, positioning the program for an IND filing and Phase 1/2 initiation later in 2026. On May 13, BriaCell added Penn Medicine's Abramson Cancer Center as a clinical site for the pivotal Phase 3 Bria-IMT metastatic breast cancer study, bringing the trial-site network to include Smilow Cancer Hospital at Yale New Haven and Los Angeles Cancer Network. The two announcements come ahead of BriaCell's six accepted ASCO 2026 abstract presentations on Bria-IMT and Bria-OTS+ in metastatic breast cancer, scheduled for the May 29-June 2 Chicago meeting. The May 6 FDA clearance for the Bria-BRES+ clinical study completes a busy two-week operational cadence for the company.
ASCO 2026 abstracts will release on asco.org/abstracts beginning 5:00 PM ET on Wednesday May 21, ahead of the May 29-June 2 Chicago meeting. The peptide-oncology slate is substantial: Pfizer announced 40+ company-sponsored, investigator-sponsored, and collaborative oncology abstracts including three late-breaking sessions; Bicycle Therapeutics has an oral and four poster presentations on zelenectide pevedotin (BT8009, nectin-4 PDC) with Duravelo-2 interim data; Avacta has Phase Ia/Ib data on AVA6000 (FAP-Dox PDC) in salivary gland cancers; BioVaxys's MVP-S survivin peptide vaccine PESCO trial data; BriaCell's six Bria-IMT/Bria-OTS+ presentations on metastatic breast cancer; and Replimune's RP1 + nivolumab 3-year melanoma OS data. Crinetics CRN09682 SSTR2 NDC BRAVESST2 update expected.
BriaCell announced April 21 preclinical results from its next-generation Bria-OTS+ personalized peptide immunotherapy at the AACR 2026 Annual Meeting. The platform pairs HLA-matched whole-cell allogeneic immunotherapy with peptide-mediated antigen targeting, building on the Bria-IMT clinical foundation in heavily pretreated metastatic breast cancer. Based on the preclinical anti-cancer activity, BriaCell plans to enter the clinic for metastatic breast cancer and prostate cancer indications later in 2026, with lung cancer and melanoma planned for 2027. The program adds to a peptide-immuno-oncology pipeline that includes the Bria-IMT Phase 3 and the company's six accepted ASCO 2026 presentations covering survival data, biomarkers, and quality-of-life endpoints.
BriaCell announced April 27 that its Bria-IMT cell-based peptide immunotherapy will be featured in three poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago). Highlights include 12- and 24-month overall survival data with Bria-IMT plus checkpoint inhibition in advanced metastatic breast cancer, an updated quality-of-life and tolerability analysis, and a randomized Bria-ABC Phase 3 blood-biomarker progression-free survival readout. Three publication-only abstracts cover the second-generation BC1 platform, multi-analyte liquid biopsy stratification, and PD-L1 monitoring in circulating cancer-associated cells.
BriaCell's Bria-IMT + checkpoint inhibitor combination preserved overall health status and key functional quality-of-life measures in its pivotal Phase 3 study in heavily pretreated metastatic breast cancer patients who had failed ADC, CPI, and CDK4/6 inhibitor therapy. Phase 2 biomarker analyses identified mitotic circulating tumor cells as prognostic and PD-L1 in tumor-macrophage fusion cells as predictive of checkpoint benefit. Presented at AACR April 20.